SDEVNYSEFinance ServicesFiscal year ends December 31
Stablecoin Development Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$0.84−0.04 (-4.81%)
Close on Oct 19, 2026
- Market cap
- $26.03M
- P/E (TTM)
- –
- Dividend yield
- 477.10%
Stablecoin Development Corp revenue by segment
By business segment
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ophthalmology [Member] | – | – | – | – | – | – | – | – | – | $329.00K | – | – |
| Wound Care [Member] | – | – | – | – | – | – | – | – | – | $471.00K | – | – |
| Dermatology [Member] | – | – | – | – | – | – | – | – | – | $5.00K | – | – |
| Other Segments [Member] | – | – | – | – | – | – | – | – | – | $249.00K | – | – |
| Optical and Wound Care [Member] | – | $11.17M | $10.24M | $9.56M | – | – | – | – | – | – | – | – |
| Skin Care [Member] | – | $3.55M | $4.17M | $649.00K | – | – | – | – | – | – | – | – |
| Skincare [Member] | – | – | – | $587.00K | – | – | – | – | – | – | – | – |
| Operating income | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ophthalmology [Member] | – | – | – | – | – | – | – | – | – | -$7.95M | – |
| Wound Care [Member] | – | – | – | – | – | – | – | – | – | -$4.52M | – |
| Dermatology [Member] | – | – | – | – | – | – | – | – | – | -$1.33M | – |
| Urology [Member] | – | – | – | – | – | – | – | – | – | -$2.30M | – |
| Other Segments [Member] | – | – | – | – | – | – | – | – | – | -$776.00K | – |
| Optical and Wound Care [Member] | – | -$3.65M | -$5.65M | -$8.68M | – | – | – | – | – | – | – |
| Skin Care [Member] | – | -$3.95M | -$8.77M | -$180.00K | – | – | – | – | – | – | – |
By product or service
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $9.75M | $10.46M | $14.37M | $10.18M | $9.92M | $6.56M | $12.47M | $18.13M | $11.62M | – | 99.7% | -6.8% |
| Total Product Revenue [Member] | $9.75M | $10.46M | $14.37M | $10.18M | $9.92M | $6.56M | $12.47M | – | – | – | 99.7% | -6.8% |
| Avenova Spray [Member] | $8.67M | $7.81M | $7.65M | $8.57M | $5.97M | $6.35M | – | – | – | – | 88.7% | +11.1% |
| Avenova Product [Member] | $7.20M | $6.10M | $6.50M | – | $5.97M | $6.35M | $12.31M | – | – | – | 73.6% | +18.0% |
| Other Products [member] | $1.07M | $1.27M | $1.59M | $598.00K | $294.00K | $0 | – | – | – | – | 11.0% | -15.6% |
| Product and Service, Other [Member] | $34.00K | $0 | $30.00K | $24.00K | $18.00K | $43.00K | $34.00K | $103.00K | $280.00K | – | 0.3% | – |
| NeutroPhase [Member] | $0 | $1.38M | $976.00K | $368.00K | $524.00K | $209.00K | $169.00K | – | – | – | 0.0% | -100.0% |
| KN95 Masks [Member] | – | – | – | $0 | $3.12M | $0 | $0 | – | – | – | – | – |
| Avenova Direct [Member] | – | – | $6.50M | $6.60M | $3.30M | $1.00M | – | – | – | – | – | – |
| DERMAdoctor [Member] | – | $3.55M | $4.16M | $649.00K | $0 | $0 | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Stablecoin Development's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.